Physician

Alan C Dejarnatt, MD

According to 2025 Medicare claims, Alan Dejarnatt, MD (NPI: 1598750184) practices allergy/immunology in the Jackson, TN market, with the plurality of this provider's patient population coming from Madison, TN. This provider's primary affiliated billing organization is PSF PLLC (NPI: 1881785947; TIN: 611389493) and primary practice location at 38305-2810.

Dejarnatt's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 288 traditional Medicare patients, billed 19,541 HCPCS/CPT codes, and received $457,714 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 1,240 prescription claims across 256 beneficiaries totaling $1,909,253 in drug costs, led by Icatibant (Icatibant Acetate). DME data shows 101 claims. Open Payments data shows 46 records totaling $941. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $64,937 to $457,714. Similarly, Part D prescription costs have moved sharply higher in recent years, from $75,449 to $1,909,253. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $767 and ending at $2,698.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	355	7,369	$64,937
2016	339	6,613	$55,085
2017	355	7,249	$59,983
2018	414	8,365	$67,554
2019	392	7,258	$59,782
2020	347	8,148	$80,957
2021	302	11,262	$196,136
2022	284	13,728	$286,630
2023	301	17,676	$368,380
2024	288	19,541	$457,714

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	256	1,151	$75,449
2016	246	1,272	$110,782
2017	242	1,231	$153,814
2018	295	1,414	$212,460
2019	293	1,338	$231,334
2020	263	1,058	$203,475
2021	247	1,168	$314,061
2022	245	1,306	$380,079
2023	263	1,200	$396,697
2024	256	1,240	$1,909,253

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	43	$3,754
2016	N/R	47	$2,969
2017	N/R	N/R	N/R
2018	N/R	51	$1,909
2019	N/R	29	$135
2020	N/R	32	$80,332
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	79	$1,812
2024	N/R	101	$100,907

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	42	42	$103
99203	New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more	61	61	$70
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	157	164	$56
95165	Professional service for preparation and provision of 1 or more antigens	96	1,860	$10
95004	Test for allergy using allergenic extract	68	3,073	$2

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Icatibant	Icatibant Acetate	44	44	$766,904
Dupixent Pen	Dupilumab	43	1,190	$171,347
Gamunex-C	Immune Globul G/Gly/Iga Avg 46	12	336	$65,483
Hizentra	Immun Glob G(Igg)/Pro/Iga 0-50	17	476	$58,744
Xolair	Omalizumab	15	420	$45,042

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1555	Injection, immune globulin (cuvitru), 100 mg	N	N/R	12	$61,430
J1559	Injection, immune globulin (hizentra), 100 mg	N	N/R	13	$36,967
A4221	Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately)	N	N/R	24	$1,844
Q0513	Pharmacy dispensing fee for inhalation drug(s); per 30 days	N	N/R	13	$310
K0552	Supplies for external non-insulin drug infusion pump, syringe type cartridge, sterile, each	N	N/R	24	$247

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	46	$941	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Alan C. Dejarnatt, MD?

Tedicare shows public-source Medicare data for Alan C. Dejarnatt, MD (NPI 1598750184), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alan C. Dejarnatt, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Alan C. Dejarnatt, MD?

Alan C. Dejarnatt, MD is linked to PSF PLLC (billing NPI 1881785947) in the available physician profile data.

Does Alan C. Dejarnatt, MD have Open Payments data?

Alan C. Dejarnatt, MD has 46 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.